• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Insulet stock rises on Street-beating Q3, raised sales guidance

November 3, 2022 By Sean Whooley

InsuletInsulet (Nasdaq:PODD) shares ticked up after hours today on third-quarter results that came in ahead of the consensus forecast.

Shares of PODD rose 8.1% at $276 apiece after the market closed today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the day down 3.8%.

The Acton, Massachusetts-based company posted a $5.2 million loss for the quarter. That equals 8¢ per share on sales of $340.8 million for the three months ended Sept. 30, 2022.

Insulet recorded a bottom-line dip into the red from profits of $12.6 million this time last year. However, the company registered sales growth of 23.7% year-over-year.

The company reported total Omnipod automated insulin delivery system revenue of $326.1 million. Insulet earlier this year initiated the full market launch of the latest-generation Omnipod 5 device in U.S. pharmacies.

Additionally, Insulet said it recently developed a basal-only pod for individuals with type 2 diabetes. It plans to submit to the FDA for 510(k) clearance soon, according to a news release.

Adjusted to exclude one-time items, Insulet reported earnings per share of 45¢. That comes in 30¢ ahead of expectations on Wall Street. Insulet recorded a sales beat, too, as analysts projected revenues of $312.5 million.

Insulet expects “another year of strong growth”

“Our third quarter accomplishments demonstrate the continued execution and commitment of the entire Insulet team,” said Jim Hollingshead, president and CEO. “Omnipod 5 U.S. adoption is exceeding our expectations and proving to be the game-changer we knew it would be. We are thrilled to have received CE Mark approval to bring Omnipod 5 to international markets and to have expanded Omnipod 5’s indication down to age two.

“We expect to deliver another year of strong growth and operational progress and enter 2023 with significant momentum across our business. We have never been in a stronger position to deliver on our mission to simplify and improve the lives of people with diabetes.”

For the second consecutive quarter, Insulet announced an increase in its annual revenue guidance. Last quarter, it increased its projections from 12%-16% growth to 14%-17%. Today, the company said it now expects a year-over-year improvement of 18%-19%.

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Patient Monitoring, Technology, Wall Street Beat Tagged With: Insulet

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS